Delphia (Usa) Inc. Allogene Therapeutics, Inc. Transaction History

Delphia (Usa) Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $59,583 - $88,651	-13,153 Reduced 48.96%	13,714 $68,000
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $22,002 - $36,715	-4,472 Reduced 14.27%	26,867 $132,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $46,095 - $91,124	8,202 Added 35.45%	31,339 $197,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $150,424 - $251,873	-14,576 Reduced 38.65%	23,137 $250,000
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $150,949 - $273,401	22,264 Added 144.11%	37,713 $430,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $39,978 - $79,905	5,226 Added 51.12%	15,449 $141,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $134,227 - $250,667	10,223 New	10,223 $153,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

Stay updated on Delphia (Usa) Inc. with notifications on news.